The AJR group
Dr Graham Wynne
Graham Wynne studied at the University of Nottingham gaining his BSc (Hons) in 1992 and PhD in 1995 under the supervision of Professor Gerry Pattenden. Following postdoctoral work with Professor Lew Mander at ANU (Canberra), he joined Aston Molecules Ltd, later OSI Pharmaceuticals where he led the chemistry team that discovered OSI-930, a dual kit-KDR kinase inhibitor which progressed into clinical trials. In 2005 he joined the University of Oxford spin-out company VASTOx Ltd (now Summit Therapeutics plc) leading the medicinal chemistry team which discovered ezutromid, a potential first-in-class treatment for Duchenne Muscular Dystrophy which progressed to Phase 2 clinical trials. Since 2009 he has worked at the University of Oxford with AJR and Professor Steve Davies on various drug discovery targets, including oncology, muscular dystrophy and stem cell modulation. Graham has also co-founded a number of companies, including MuOx (acquired by Summit plc) and OxStem Neuro (subsidiary of OxStem Ltd).